Krystal Biotech (KRYS) Cash from Operations Growth (3y) (2019 - 2026)
Powered by 
Analysis
Krystal Biotech (KRYS) Cash from Operations Growth (3y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -0.27% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -7.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 16.85% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 52.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 96.08% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 6.22% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.23% |
| 10 | Krystal Biotech | 10.61 Bn | 9.76 Bn | 112.79 Mn | 61.18% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 61.18% |
| Mar 31, 2026 | 71.83% |
| Dec 31, 2025 | 76.21% |
| Sep 30, 2025 | 58.93% |
| Jun 30, 2025 | 47.74% |
| Mar 31, 2025 | 58.73% |
| Dec 31, 2024 | 65.44% |
| Sep 30, 2024 | 116.25% |
| Jun 30, 2024 | 25.62% |
| Mar 31, 2024 | 53.91% |
| Dec 31, 2023 | 3.40% |
| Sep 30, 2023 | -46.30% |
| Jun 30, 2023 | -89.13% |
| Mar 31, 2023 | -61.35% |
| Dec 31, 2022 | -47.21% |
| Sep 30, 2022 | -66.49% |
| Jun 30, 2022 | -117.08% |
| Mar 31, 2022 | -68.91% |
| Dec 31, 2021 | -81.11% |
| Sep 30, 2021 | -55.22% |